Accelerate Diagnostics, Inc.

Good day, and welcome to the Accelerate Diagnostics, Inc. 2023 Q2 Results Conference Call. Today, all participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions during the session. Please note, this event is being recorded. I would now like to turn the conference over to Laura Pearson of Accelerate Diagnostics. Please go ahead.

Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements that are made during this conference call are subject to risk, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year ended December 31st, 2022, and other reports we file with the SEC. It is my pleasure to now introduce the company's president and CEO, Jack Phillips.

Thank you, Laura. Good afternoon and welcome to our second quarter earnings call. Today's call will focus on our second quarter results and include several updates on our strategic priorities. My commentary will focus on our top three strategic priorities. First, I would like to review our innovation advancements with our next generation susceptibility platform, WAVE. Our second priority is to continue to grow market share through our Beckton Dickinson partnership with Fino, and our sample preparation instrument, ARC. And finally, continuing to build financial strength, which I will touch on, closing out our debt restructuring transaction and reducing our cash burn. Before I discuss these important strategic priorities further, I'd like to hand it over to our Chief Financial Officer, David Patience, to review our preliminary second quarter financial results.